137 related articles for article (PubMed ID: 38149816)
1. Up-regulation of TNF-alpha/NFkB/SIRT1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma.
de Castro LR; de Oliveira LD; Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida OGG; Amorim MLM; Squarize CH; Castilho RM; de Almeida LO
J Cell Physiol; 2024 Feb; 239(2):e31164. PubMed ID: 38149816
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of HDAC6 overcomes cisplatin chemoresistance by targeting cancer stem cells in oral squamous cell carcinoma.
Tavares MO; Milan TM; Bighetti-Trevisan RL; Leopoldino AM; de Almeida LO
J Oral Pathol Med; 2022 Jul; 51(6):529-537. PubMed ID: 35678235
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal transition and cancer stem cells: A route to acquired cisplatin resistance through epigenetics in HNSCC.
Lima de Oliveira J; Moré Milan T; Longo Bighetti-Trevisan R; Fernandes RR; Machado Leopoldino A; Oliveira de Almeida L
Oral Dis; 2023 Jul; 29(5):1991-2005. PubMed ID: 35403781
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin.
Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida LO
Arch Oral Biol; 2022 Sep; 141():105468. PubMed ID: 35679799
[TBL] [Abstract][Full Text] [Related]
5. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
7. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
8. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
[TBL] [Abstract][Full Text] [Related]
9. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line.
Xiong P; Li YX; Tang YT; Chen HG
Protein J; 2011 Oct; 30(7):499-508. PubMed ID: 21947960
[TBL] [Abstract][Full Text] [Related]
11. Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets.
Milan TM; Eskenazi APE; Oliveira LD; Silva GD; Bighetti-Trevisan RL; Freitas GP; Almeida LO
Cell Signal; 2023 Sep; 109():110773. PubMed ID: 37331417
[TBL] [Abstract][Full Text] [Related]
12. METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.
Qiao X; Zhu L; Song R; Shang C; Guo Y
Oral Dis; 2023 Apr; 29(3):942-956. PubMed ID: 34807506
[TBL] [Abstract][Full Text] [Related]
13. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
[TBL] [Abstract][Full Text] [Related]
14. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
16. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma.
Tsai LL; Yu CC; Chang YC; Yu CH; Chou MY
J Oral Pathol Med; 2011 Sep; 40(8):621-8. PubMed ID: 21342274
[TBL] [Abstract][Full Text] [Related]
17. pERK-mediated IL8 secretion can enhance the migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells.
Pu Y; Li Q; Wang Y; Xu L; Qiao Q; Guo Y; Guo C
BMC Cancer; 2021 Dec; 21(1):1283. PubMed ID: 34847866
[TBL] [Abstract][Full Text] [Related]
18. Pluripotency transcription factor Nanog and its association with overall oral squamous cell carcinoma progression, cisplatin-resistance, invasion and stemness acquisition.
Kashyap T; Nath N; Mishra P; Jha A; Nagini S; Mishra R
Head Neck; 2020 Nov; 42(11):3282-3294. PubMed ID: 32710593
[TBL] [Abstract][Full Text] [Related]
19. WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway.
Zhang X; Sun K; Gan R; Yan Y; Zhang C; Zheng D; Lu Y
BMC Cancer; 2024 May; 24(1):564. PubMed ID: 38711026
[TBL] [Abstract][Full Text] [Related]
20. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
